• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, November 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Symptom burden may increase hospital length of stay, readmission risk in advanced cancer

Bioengineer by Bioengineer
October 23, 2017
in Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Hospitalized patients with advanced cancer who report more intense and numerous physical and psychological symptoms appear to be at risk for longer hospital stays and unplanned hospital readmissions. The report from a Massachusetts General Hospital (MGH) research team, published online in the journal Cancer, is one of the first to focus on symptom prevalence and severity among hospitalized patients with cancer and the first to demonstrate a relationship between uncontrolled symptoms and the use of health care services.

"Hospitalized patients with advanced cancer experience an immense burden of physical and psychological symptoms," says Ryan Nipp MD, of the MGH Cancer Center, co-lead and corresponding author of the Cancer paper. "Patients' symptoms represent potentially modifiable risk factors, and prior research has shown that interventions aimed at symptom improvement can enhance patient-reported outcomes. We found novel results regarding the relationship between patients' symptoms and their use of health care services, which highlight the critical need to develop and test interventions addressing the symptoms experienced by hospitalized patients with advanced cancer to improve both the care these patients receive and their utilization of health care services."

The study enrolled 1,036 patients with advanced cancer – defined as those receiving treatment focused on comfort or symptom relief, rather than an attempt to cure their disease – with unplanned admissions to the MGH from September 2104 through May 2016. Upon admission, participants completed several surveys designed to assess the presence of physical symptoms – such as pain, fatigue, drowsiness, nausea, poor appetite and shortness of breath – and symptoms of depression and anxiety.

More than half of the participating patients reported currently experiencing moderate to severe fatigue, pain, drowsiness, lack of appetite or poor overall well-being. More than a quarter reported significant levels of depression or anxiety symptoms. Patients' physical symptoms were significantly associated with longer hospital lengths of stay and increased risk of unplanned readmission within 90 days. Overall psychological distress and depression scores were associated with longer lengths of stay, while patients' anxiety symptoms were associated with higher readmission risk.

"We know that hospitalized patients with advanced cancer often experience a higher symptom burden compared with those treated in the outpatient setting, but until now, most efforts to improve symptom management have focused on ambulatory patients," says Nipp, who is an instructor in Medicine at Harvard Medical School. "There is a critical need to focus on efforts to alleviate suffering among hospitalized patients with advanced cancer. For example, future efforts should determine the efficacy of implementing symptom monitoring and supportive care interventions for such patients in an effort to relieve their symptoms, improve quality of life and enhance the quality of their cancer care."

###

Areej El-Jawahri, MD, of the MGH Cancer Center is co-lead author of the Cancer paper, and Jennifer Temel, MD, MGH Cancer Center, is senior author. Additional co-authors are Connor Johnson, MD, Daniel Lage, MD, Risa Wong, MD, Inga Lennes, MD, MPH, MBA, Barbara Cashavelly, RN, David Ryan, MD, and Ephraim Hochberg, MD, MGH Cancer Center; Samantha Moran, Sara D'Arpino, Lara Traeger, PhD, and Joseph Greer, PhD, MGH Department of Psychiatry; William Pirl, MD, MPH, University of Miami, Florida; and Vicki Jackson, MD, MPH, MGH Division of Palliative Care. Support for the study includes National Institutes of Health grant K24 CA181253, MGH Cancer Center Funds, and the Scullen Center for Cancer Data Analysis.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $850 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."

Media Contact

Katie Marquedant
[email protected]
617-726-0337
@MassGeneralNews

http://www.mgh.harvard.edu

http://dx.doi.org/10.1002/cncr.30912

Share12Tweet8Share2ShareShareShare2

Related Posts

Insights on Eosinophilic Granulomatosis with Polyangiitis: A Podcast

November 1, 2025
blank

Boosting Lettuce Yields with Steel Slag Compost Teas

November 1, 2025

Comparing Immune Responses: Rituximab vs. Obinutuzumab in Follicular Lymphoma

November 1, 2025

β-Hydroxybutyrate Protects Against Early Diabetic Kidney Disease

November 1, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1295 shares
    Share 517 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    203 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    137 shares
    Share 55 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Insights on Eosinophilic Granulomatosis with Polyangiitis: A Podcast

Boosting Lettuce Yields with Steel Slag Compost Teas

Comparing Immune Responses: Rituximab vs. Obinutuzumab in Follicular Lymphoma

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.